Yvonne N Flores1,2, Allyn Auslander3, Catherine M Crespi4, Michael Rodriguez5, Zuo-Feng Zhang3, Francisco Durazo6, Jorge Salmerón1,7. 1. Unidad de Investigación Epidemiológica y en Servicios de Salud, Instituto Mexicano del Seguro Social, Cuernavaca, Morelos, México. 2. Department of Health Policy and Management, Center for Cancer Prevention and Control Research, Fielding School of Public Health and Jonsson Comprehensive Cancer Center, Los Angeles, California, USA. 3. Department of Epidemiology, Fielding School of Public Health, UCLA, Los Angeles, California, USA. 4. Department of Biostatistics, Center for Cancer Prevention and Control Research, Fielding School of Public Health and Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, USA. 5. Department of Family Medicine, David Geffen School of Medicine, UCLA, Los Angeles, California, USA. 6. Department of Digestive Diseases, David Geffen School of Medicine and Pfleger Liver Institute, UCLA, Los Angeles, California, USA. 7. Centro de Investigación en Salud Poblacional, Instituto Nacional de Salud Pública, Cuernavaca, Morelos, Mexico.
Abstract
OBJECTIVE: In Mexico, chronic liver disease have been increasingly found along with the rapidly growing prevalence of obesity, diabetes and metabolic syndrome (MS). We aimed to investigate the longitudinal association between these three factors and risk of elevated alanine aminotransferase (ALT) levels (>40 U/L), a marker for liver damage, in a cohort of Mexican adults. METHODS: Data were obtained from two separate waves of the Mexican Health Worker Cohort Study: Wave 1 (2004-2006) and Wave 2 (2011-2013). Unconditional logistic regression models were employed to determine the cross-sectional and longitudinal association between these risk factors and elevated ALT levels. RESULTS: The prevalence of elevated ALT was significantly higher among men, individuals aged under 60 years, those who were overweight or obese, diabetic, with MS or heavy/binge drinkers. The longitudinal results indicated that weight gain between waves that resulted in a change in body mass index, along with remaining overweight or obese, were significantly associated with an increased risk of elevated ALT levels. A significantly increased risk of developing elevated ALT was also observed among those who acquired diabetes or MS from Wave 1 to Wave 2. CONCLUSIONS: Weight gain and acquiring diabetes or MS are associated with a significant risk of having elevated ALT. These results, within the context of the rapid increase in global obesity rates, call urgently for programs to help to prevent chronic liver disease.
OBJECTIVE: In Mexico, chronic liver disease have been increasingly found along with the rapidly growing prevalence of obesity, diabetes and metabolic syndrome (MS). We aimed to investigate the longitudinal association between these three factors and risk of elevated alanine aminotransferase (ALT) levels (>40 U/L), a marker for liver damage, in a cohort of Mexican adults. METHODS: Data were obtained from two separate waves of the Mexican Health Worker Cohort Study: Wave 1 (2004-2006) and Wave 2 (2011-2013). Unconditional logistic regression models were employed to determine the cross-sectional and longitudinal association between these risk factors and elevated ALT levels. RESULTS: The prevalence of elevated ALT was significantly higher among men, individuals aged under 60 years, those who were overweight or obese, diabetic, with MS or heavy/binge drinkers. The longitudinal results indicated that weight gain between waves that resulted in a change in body mass index, along with remaining overweight or obese, were significantly associated with an increased risk of elevated ALT levels. A significantly increased risk of developing elevated ALT was also observed among those who acquired diabetes or MS from Wave 1 to Wave 2. CONCLUSIONS:Weight gain and acquiring diabetes or MS are associated with a significant risk of having elevated ALT. These results, within the context of the rapid increase in global obesity rates, call urgently for programs to help to prevent chronic liver disease.
Authors: Seung H Park; Woo K Jeon; Sang H Kim; Hong J Kim; Dong I Park; Yong K Cho; In K Sung; Chong I Sohn; Dong K Keum; Byung I Kim Journal: J Gastroenterol Hepatol Date: 2006-01 Impact factor: 4.029
Authors: Yvonne N Flores; Hal F Yee; Mei Leng; José J Escarce; Roshan Bastani; Jorge Salmerón; Leo S Morales Journal: Am J Gastroenterol Date: 2008-07-30 Impact factor: 10.864
Authors: Mariana Lazo; Ruben Hernaez; Mark S Eberhardt; Susanne Bonekamp; Ihab Kamel; Eliseo Guallar; Ayman Koteish; Frederick L Brancati; Jeanne M Clark Journal: Am J Epidemiol Date: 2013-05-23 Impact factor: 4.897
Authors: Wolfram Goessling; Joseph M Massaro; Ramachandran S Vasan; Ralph B D'Agostino; R Curtis Ellison; Caroline S Fox Journal: Gastroenterology Date: 2008-09-20 Impact factor: 22.682
Authors: Clicerio González-Villalpando; Claudio Alberto Dávila-Cervantes; Mireya Zamora-Macorra; Belem Trejo-Valdivia; María Elena González-Villalpando Journal: Salud Publica Mex Date: 2014 Jan-Feb
Authors: Philip R Spradling; Lisa Bulkow; Eyasu H Teshale; Susan Negus; Chriss Homan; Brenna Simons; Brian J McMahon Journal: J Hepatol Date: 2014-06-06 Impact factor: 25.083
Authors: Zheming Yu; Hamed Samavat; Allison M Dostal; Renwei Wang; Carolyn J Torkelson; Chung S Yang; Lesley M Butler; Thomas W Kensler; Anna H Wu; Mindy S Kurzer; Jian-Min Yuan Journal: Cancer Prev Res (Phila) Date: 2017-08-01